Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ferdeghini

Showing results (71-80 of 167) with videos related to

Pageof 17
Sort By:
Renal Failure|May 9, 1998
Serum levels of tumor associated trypsin inhibitor (TATI) and glomerular filtration rateG Tramonti, M Ferdeghini, C Donadio, et al.
The Journal of Nuclear Medicine and Allied Sciences|July 1, 1989
The trend of serum CA125 levels during the first three courses of chemotherapy as a predictor of second-look findings in patients with ovarian carcinomaA Gadducci, M Ferdeghini, T Bartolini, et al.
Oncology Reports|May 20, 2011
Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in patients with cervical cancerA Gadducci, M Ferdeghini, A Fanucchi, et al.
The Journal of Clinical Investigation|August 1, 1987
Role of serum carrier proteins in the peripheral metabolism and tissue distribution of thyroid hormones in familial dysalbuminemic hyperthyroxinemia and congenital elevation of thyroxine-binding globulinR Bianchi, G Iervasi, A Pilo, et al.
Informatics for Health & Social Care|August 19, 2011
Telematic integration of health data: a practicable contributionLorenzo Guerriero, Ezio M Ferdeghini, Silvia R Viola, et al.
European Journal of Gynaecological Oncology|January 1, 1990
A comparison of the usefulness of serum measurements of CA 125, CA 50 and TATI in patients with malignant and benign gynecological pathologyA Gadducci, M Ferdeghini, V Facchini, et al.
European Journal of Gynaecological Oncology|January 1, 1990
A comparative evaluation of the ability of serum CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinomaA Gadducci, M Ferdeghini, T Ceccarini, et al.
The Journal of Nuclear Medicine and Allied Sciences|July 1, 1989
External quality control survey for alpha-fetoprotein assayG C Zucchelli, A Pilo, M Ferdeghini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotideS Ricci, A Antonuzzo, L Galli, et al.
The American Journal of Medicine|October 20, 1999
Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjectsF Carmassi, M Morale, L Ferrini, et al.
Pageof 17

Showing results (71-80 of 167) with videos related to

Sort By:
Pageof 17
Renal Failure|May 9, 1998
Serum levels of tumor associated trypsin inhibitor (TATI) and glomerular filtration rateG Tramonti, M Ferdeghini, C Donadio, et al.
The Journal of Nuclear Medicine and Allied Sciences|July 1, 1989
The trend of serum CA125 levels during the first three courses of chemotherapy as a predictor of second-look findings in patients with ovarian carcinomaA Gadducci, M Ferdeghini, T Bartolini, et al.
Oncology Reports|May 20, 2011
Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in patients with cervical cancerA Gadducci, M Ferdeghini, A Fanucchi, et al.
The Journal of Clinical Investigation|August 1, 1987
Role of serum carrier proteins in the peripheral metabolism and tissue distribution of thyroid hormones in familial dysalbuminemic hyperthyroxinemia and congenital elevation of thyroxine-binding globulinR Bianchi, G Iervasi, A Pilo, et al.
Informatics for Health & Social Care|August 19, 2011
Telematic integration of health data: a practicable contributionLorenzo Guerriero, Ezio M Ferdeghini, Silvia R Viola, et al.
European Journal of Gynaecological Oncology|January 1, 1990
A comparison of the usefulness of serum measurements of CA 125, CA 50 and TATI in patients with malignant and benign gynecological pathologyA Gadducci, M Ferdeghini, V Facchini, et al.
European Journal of Gynaecological Oncology|January 1, 1990
A comparative evaluation of the ability of serum CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinomaA Gadducci, M Ferdeghini, T Ceccarini, et al.
The Journal of Nuclear Medicine and Allied Sciences|July 1, 1989
External quality control survey for alpha-fetoprotein assayG C Zucchelli, A Pilo, M Ferdeghini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotideS Ricci, A Antonuzzo, L Galli, et al.
The American Journal of Medicine|October 20, 1999
Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjectsF Carmassi, M Morale, L Ferrini, et al.
Pageof 17